SCHEMBL3755853

SCHEMBL3755853

CN(C)C(=O)Sc1ccc(C#N)c(F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.43
TRPV4 Q9HBA0 1/20 0.41
DAO P14920 1/20 0.40
CYP11B2 P19099 7/20 0.40
CYP11B1 P15538 6/20 0.40
KDM4E B2RXH2 1/20 0.37
CYP1A2 P05177 1/20 0.37
GLA P06280 1/20 0.37
CYP3A4 P08684 1/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
EGLN2 Q96KS0 1/20 0.37
ACHE P22303 1/20 0.36
SLC22A12 Q96S37 1/20 0.36
S1PR3 Q99500 2/20 0.36
TRPA1 O75762 1/20 0.35
KCNQ3 O43525 1/20 0.34
KCNQ2 O43526 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3745566 0.82 ALDH1A1 (0.43) ALDH1A1TRPV4DAOCYP11B2KDM4E
SCHEMBL30014656 0.79 ALDH1A1 (0.43) ALDH1A1KDM4ECYP1A2GLACYP3A4
SCHEMBL22829871 0.79 ALDH1A1 (0.43) ALDH1A1KDM4ECYP1A2GLACYP3A4
SCHEMBL29019222 0.76 ALDH1A1 (0.47) ALDH1A1KDM4EGAAMAPTACHE
SCHEMBL3949266 0.75 TRPV4 (0.56) ALDH1A1TRPV4DAOCYP11B2GAA
SCHEMBL9352583 0.74 NCEH1 (0.45) ALDH1A1CYP11B2CYP11B1MAPTACHE
SCHEMBL2580324 0.74 ALDH1A1 (0.43) ALDH1A1KDM4EMAPT
SCHEMBL19656599 0.73 CYP11B2 (0.47) DAOCYP11B2CYP11B1EGLN2SLC22A12
SCHEMBL3753297 0.73 CYP11B1 (0.58) TRPV4DAOCYP11B2CYP11B1
SCHEMBL16978031 0.73 S1PR3 (0.47) ALDH1A1TRPV4CYP11B2CYP11B1S1PR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022015624-A1 SUBSTITUTED DIHYDROPYRAZINEDIONES AS MODULATORS OF THE NMDA RECEPTOR SCHRÖDINGER, INC. (US) 2022-01-20 WO disclosed
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias ASTRAZENECA AB (SE) 2010-11-25 US disclosed
EP-2049484-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS AstraZeneca AB (SE) 2009-04-22 EP disclosed
WO-2008008022-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS ASTRAZENECA AB (SE) 2008-01-17 WO disclosed
US-20080015237-A1 NEW COMPOUNDS I/418 ASTRAZENECA AB (SE) 2008-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015237-A1 NEW COMPOUNDS I/418 KCNH1, KCNH2, KCNH3 ALDH1A1 315/4885TRPV4 535/4885DAO 700/4885
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias KCNH1, KCNH2, KCNQ2 ALDH1A1 310/4885TRPV4 541/4885DAO 1307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.